|
Mar 3
|
TG Therapeutics: Q4 Earnings Snapshot
|
|
Mar 3
|
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
|
|
Feb 27
|
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
|
|
Feb 26
|
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update
|
|
Feb 25
|
Institutional investors in TG Therapeutics, Inc. (NASDAQ:TGTX) see US$243m decrease in market cap last week, although long-term gains have benefitted them.
|
|
Feb 12
|
How Small, But 'Mighty' TG Therapeutics Scored A 470% Gain Over 13 Months
|